Agents and methods using thereof for the prevention and treatment of stem cells senescence
US-2019054098-A1 · Feb 21, 2019 · US
Agents and methods using thereof for the prevention and treatment of stem cell muscle disorders
US10905704B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10905704-B2 |
| Application number | US-201615758365-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 7, 2016 |
| Priority date | Sep 8, 2015 |
| Publication date | Feb 2, 2021 |
| Grant date | Feb 2, 2021 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to agents that induce mitochondrial unfolded protein response (UPR mt) in muscle stem cells and prevents or reverse process of muscle stem cell senescence. Further, the invention relates to methods and compositions useful in the prevention and/or treatment of muscle stem senescence.
First claim
Opening claim text (preview).
The invention claimed is: 1. A method of cell-based therapy, said method comprising administering or grafting a skeletal muscle stem cell composition comprising skeletal muscle stem cells and at least one UPR mt inducing agent selected from nicotinamide riboside (NR), thiamphenicol (TAP) and analogues thereof to a subject. 2. A method of cell-based therapy in a subject, said method comprising administering a composition comprising at least one UPR mt inducing agent selected from nicotinamide riboside (NR), thiamphenicol (TAP) and analogues thereof and wherein said at least one UPR mt inducing agent is administered in combination with one or more replacement therapies using allogenic or autologous muscle stem cells. 3. The method according to claim 1 , wherein said at least one UPRmt inducing agent is nicotinamide riboside (NR). 4. The method according to claim 1 , wherein said at least one UPRmt inducing agent is thiamphenicol (TAP). 5. The method according to claim 2 , wherein said at least one UPRmt inducing agent is nicotinamide riboside (NR). 6. The method according to claim 2 , wherein said at least one UPRmt inducing agent is thiamphenicol (TAP).
Assignees
Inventors
Classifications
Tetracyclines · CPC title
Drugs for disorders of the muscular or neuromuscular system · CPC title
- A61K31/706Primary
containing six-membered rings with nitrogen as a ring hetero atom · CPC title
Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts · CPC title
Nucleic acids or derivatives thereof (A23L33/145 takes precedence) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10905704B2 cover?
- The present invention relates to agents that induce mitochondrial unfolded protein response (UPR mt) in muscle stem cells and prevents or reverse process of muscle stem cell senescence. Further, the invention relates to methods and compositions useful in the prevention and/or treatment of muscle stem senescence.
- Who is the assignee on this patent?
- Ecole Polytechnique Fed Lausanne Epfl
- What technology area does this patent fall under?
- Primary CPC classification A61K31/706. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Feb 02 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).